**Name of Journal:** *World Journal of Gastrointestinal Oncology*

**Manuscript NO:** 64602

**Manuscript Type:** MINIREVIEWS

**Endoscopic ultrasound assessment and tissue acquisition of mediastinal and abdominal lymph nodes**

Tamanini G *et al*. EUS lymph nodes assessment

Giacomo Tamanini, Anna Cominardi, Nicole Brighi, Pietro Fusaroli, Andrea Lisotti

**Giacomo Tamanini, Anna Cominardi, Pietro Fusaroli, Andrea Lisotti,** Department of Gastroenterology Unit, Hospital of Imola, University of Bologna, Imola 40026, BO, Italy

**Nicole Brighi,** Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola 47014, FC, Italy

**Author contributions:** Tamanini G and Lisotti A wrote the paper, Cominardi A and Tamanini G performed data collection for systematic review; Brighi N and Fusaroli P reviewed manuscript for pivotal intellectual content.

**Corresponding author: Andrea Lisotti, MD, MSc, Adjunct Professor,** Department of Gastroenterology Unit, Hospital of Imola, University of Bologna, *via* Montericco 4, Imola 40026, BO, Italy. lisotti.andrea@gmail.com

**Received:** February 21, 2021

**Revised:** April 16, 2021

**Accepted:** July 21, 2021

**Published online:**

**Abstract**

The differential diagnosis between benign and malignant lymph nodes (LNs) has a fundamental role in the characterization and staging of malignant conditions, as well as in subsequent patients’ management. All imaging modalities (*i.e.*, computed tomography and magnetic resonance imaging) rely mainly in size; endoscopic ultrasound (EUS) criteria based on B-mode evaluation and Doppler features fail to adequately characterize with high specificity LNs nature. The introduction of EUS-elastography and contrast-enhanced harmonic EUS are useful techniques to increase the diagnostic yield in identifying metastatic LNs, to identify which suspicious LN should require pathological characterization and, finally, to target tissue acquisition. EUS-guided tissue acquisition (EUS-TA) is increasingly being used for diagnosing lymphadenopathy whenever the characterization modifies patients’ subsequent management and when no superficial LN is accessible. Since target therapy are currently available (*i.e.*, lung cancer, breast cancer), EUS-TA of malignant LNs could be required to identify tumor biology. In this field, both fine needle aspiration and biopsy needles are able to guarantee accurate results with almost perfect specificity and sub-optimal sensitivity. We finally propose a diagnostic algorithm based on most recent, high-level evidence for the diagnostic approach to suspected LNs assessment.

**Key Words:** Endoscopic ultrasound-guided tissue acquisition; Endoscopic ultrasound-fine needle aspiration; Endoscopic ultrasound-fine needle biopsy; Biopsy; Aspiration; Cancer

Tamanini G, Cominardi A, Brighi N, Fusaroli P, Lisotti A. Endoscopic ultrasound assessment and tissue acquisition of mediastinal and abdominal lymph nodes. *World J Gastrointest Oncol* 2021; In press

**Core Tip:** The characterization of suspected mediastinal or abdominal lymph nodes (LNs) represents a crucial indication for endoscopic ultrasound (EUS) and tissue acquisition, since may significantly impact patients’ management and clinical outcomes. Historically, ultrasound assessment was the first-line diagnostic modality for the evaluation of peripheral LNs. EUS allows a real-time assessment of suspected LNs located next to the gastrointestinal tract; moreover, the possibility to obtain pathological specimens from needle-based tissue acquisition allows to answer with optimal sensitivity and perfect specificity to clinical questions.

**INTRODUCTION**

Lymph nodes (LNs) are bean-shaped organs, with a variable diameter ranging between 1 and 40 mm based on the anatomical site. Around 800 LNs are present in humans, however just a small proportion can be identified on cross-sectional imaging modalities, such as computed tomography (CT) and magnetic resonance imaging (MRI). LNs are characterized by a dense connective capsule, an outer part (cortex and paracortex) which contains lymphoid follicles, and a central part (the medulla). The supplying vessels are found in the hilum, even if, in some LNs, accessory arteries and veins can enter and leave the organ through the cortex outside the hilum[1].

LNs may enlarge and change their architecture under different conditions, mainly due to acute or chronic inflammation, and neoplastic infiltration including hematological disorders[2].

The characterization of suspicious LNs has a pivotal role in clinical practice, mainly for the correct staging of malignant tumors. The N staging of Tumor-Node-Metastasis classification is essential to determine the prognosis of patients and to decide the correct medical, endoscopic or surgical approach to the disease[3-5]. However, the differential diagnosis between benign and malignant LNs through conventional imaging techniques has always been challenging. Imaging methods mostly rely on the size and shape of LNs, but these parameters seem not to be accurate, since a great part of metastatic LNs measure less than 5 mm in diameter[4-7]. Nowadays, thanks to the wide selection of therapeutic options for most thoracic and abdominal neoplasms, it is fundamental to find minimally invasive methods for more reliable LNs differential diagnosis.

**ENDOSCOPIC ULTRASOUND**

Endoscopic ultrasonography (EUS) was introduced in the clinical practice about 40 years ago and it is now used in everyday hospital routine. It has become an important technique due to its high accuracy in diagnosis and staging of a variety of benign and malignant conditions[8]. The main advantage of EUS lies in its capability to visualize the gut wall as a multi-layer structure corresponding to histologic layers and to display very closely to organs and lesions surrounding the gut wall, in particular the pancreato-biliary area, mediastinal and abdominal masses and LNs. In 1992 fine needle aspiration (FNA) has been developed as an adjunct to EUS techniques, since then it has become indispensable in clinical practice making it possible to safely obtain tissue diagnosis of most masses and lesions under the reach of EUS[9-11].

Since its introduction, the indications and role of EUS have continued to expand and it has been validated in lots of diagnostic and staging algorithms. Staging of gastrointestinal neoplasms has dramatically changed. Many studies have demonstrated that EUS is superior to CT scan for the local (T stage) and lymph node (N stage) staging of primary lesions. Recently EUS has been developing also in M staging of tumors, particularly in liver metastases evaluation. Thanks to EUS it is possible to obtain essential information to determine the resectability of a tumor, the type of intervention needed (endoscopic *vs* surgical) or the need for chemo-radiotherapy. Nowadays EUS is used not only for gastrointestinal tumors (particularly esophageal cancer, gastric cancer, pancreatic neoplasms, gastric lymphoma and rectal cancer) but also for staging of lung cancer[3,12,13].

Ultrasound (US) is the imaging method of choice for the evaluation of LNs, because of its high resolution compared to CT and MRI, thanks to its cost-effectiveness and the possibility of a real-time evaluation. For anatomical reasons conventional transcutaneous US examination is difficult or not possible in deeper regions (abdominal and mediastinal LNs); endoscopic US should be considered in such cases. Current indications for conventional US B-mode techniques are: The detection of suspicious LNs, the characterization of palpable and peri-intestinal (EUS) LNs, the staging of malignancies and the guidance for LN puncture[1,2].

To differentiate LNs we often rely on their morphologic characteristics and topographic distribution. In recent years, several studies have been conducted on the differential diagnosis between benign and malignant LNs[14,15]. Some typical aspects have been clearly depicted; for example, in the mediastinum and hepatic hilum region, the inflammatory LNs are often irregular strip or flake shaped without demarcation. In these cases, B-mode criteria could be sufficient to establish the benign nature of the LN.

Thanks to FNA/fine needle biopsy (FNB) EUS has undergone an impressive development but, nowadays, the use of EUS image enhancement techniques, such as Doppler-EUS, EUS‑real-time tissue elastography (EUS-RTE) and contrast enhancement EUS (CE-EUS), can further improve the diagnostic value of EUS in the evaluation of lymphadenopathies, focusing on architectural and vascular changes of pathologic LNs and obtaining optimal results in terms of accuracy[7,14,16-18].

**EUS IMAGE ENHANCEMENT TECHNIQUES**

***Color- and power-Doppler***

Doppler US was developed for the study of vessels and of the macrovascular architecture of organs and tissues. It includes 3 main modes: Color-Doppler, spectral Doppler, and conventional power Doppler. Color-Doppler US provides information about blood flow (like direction and mean velocity) within a selected area, superimposed on the grey-scale US image. Spectral Doppler US can detect the absolute velocity of blood flow in vessels within a small sample gate; the spectral tracing gives information about acceleration time, peak systolic and diastolic velocities, which can be used to calculate resistive indices (RI). Conventional power Doppler Ultrasonography is the most sensitive Doppler technique in the evaluation of slow flow, but it lacks directional information. It is useful in assessing global perfusion of tissues, even if it was recently overcome by the development of contrast-enhanced techniques.

Doppler modes are useful in evaluating and diagnosing vascular pathologies or in assessing vascular characteristics of normal or pathologic tissues, although some of their capabilities are limited such as the assessment of flow in vascular beds, which is too slow to be detected with these techniques. In EUS, Doppler techniques are useful in guiding invasive procedure, such as FNA/FNB or injection[19,20]. However, color-Doppler hilar vascularization, peripheral signals and spectral analysis present perfect technical results in trans-abdominal US, while in EUS the use could be limited by scope instability, LNs size and limited probe capacity.

***EUS‑elastography***

Strain imaging (“elastography”) is a real-time imaging technique for tissue characterization, which displays differences in hardness between tissues. It is based on the generation of external or internal forces (EUS elastography is based on the internal force concept) and measures compression‑induced tissue deformation (strain): Stiff tissues present lower strain and deform less under compression, while soft tissues deform more. Tissue deformation is evaluated within a region of interest (ROI) and assessed in a comparative fashion; it is then visualized using a transparent color overlay on the B‑mode image. Different pathological processes, such as fibrosis, inflammation, and cancer, can alter tissue stiffness. Elastography was initially developed for the evaluation of organs and lesions accessible from the body surface but it was subsequently combined with conventional EUS (EUS real-time elastography) with promising results, in particular in the evaluation of pancreatic lesions and LNs[21-23].

No specific patient’s preparation is needed for EUS‑elastography (EUS-E) and, even if it’s not expected to replace bioptic assessment, it can give advantages to EUS thanks to its ease of use and its low cost[21,24]. Tissue stiffness is evaluated through the application of slight compression with an US transducer to the targeted tissue; the necessary strain is provided by physiologic vascular pulsation and respiratory movements. Displacements are measured only in an axial direction; resulting tissue displacement is recorded by the EUS probe and coded by a specific software. The region immediately in front of the transducer face could be subjected to more stress than the lateral portions because of the use of a curved array transducer but, to improve uniformity in strain image, the size of the ROI can be reduced[22,25].

EUS-E is performed by using a two-panel image, with both the conventional grey-scale B-mode EUS image and the elastography image. Qualitative EUS‑RTE uses a combination of color patterns to differentiate benign and malignant lesions. Elasticity (on a scale of 1–255) is shown as a superimposed color map on a conventional B-mode image; in this elasticity map hard tissues (minor strain) are visualized by dark blue, intermediate tissue elasticity results green and yellow, whereas soft tissues (distinct strain) are shown in red (color map may be changed by the operator). For a good reliable examination, a consistent color pattern in consecutive frames is necessary. The elastography ROI should include the targeted lesion as well as the surrounding tissues as a reference. The lesion of interest should cover 25%–50% of the ROI and, in the case of a large lesion, the ROI can be placed toward the edge of the lesion[21,25,26].

Using semi-quantitative elastography the operator can obtain better results, comparing lesions to reference tissue within the ROI [strain ratio (SR)] or quantifying the distribution of strain values (strain histogram)[21]. In SR two different areas (A and B) are selected, respectively including the target lesion (without including the surrounding tissue) and a soft (red) reference tissue area outside the lesion. The ratio is defined as the quotient Mean-strain-of-B/Mean-strain-of-A and is calculated using raw strain data, not based upon color map display. Strain histogram is based on the qualitative EUS elastography data; it analyses the range and distribution of strains within a selected ROI, showing on the X-axis the elasticity of tissue from 0 (hardest) to 255 (softest). Moreover, it displays several key parameters such as mean strain, standard deviation, percent, and complexity of the blue area[22,27]. Qualitative EUS-E or semi-quantitative EUS-E (SR or Hue histogram) present low reproducibility and standardization. The introduction of quantitative EUS shear-wave measurement failed, to date, to demonstrate any advantage compared to EUS-E.

EUS-E has no formal contraindication. Over the past years EUS-E was used as a complementary method to other techniques for the evaluation of pancreatic lesions and lymph-nodes, but it has been progressively included in clinical evaluation of other lesions, such as subepithelial lesions of the GI tract and focal liver lesions[22].

***Contrast-enhanced EUS***

Contrast-enhanced EUS is an EUS ancillary technique which combines the advantage of EUS with the administration of US contrast agents. Contrast agents consist of gas-filled microbubbles, covered with a phospholipid or lipid shell, of approximately 2 to 5 μm diameter, which resonate and are disrupted when receive US waves, producing a signal detected in the US image[28,29]. They present a pure intravascular distribution, so that they do not diffuse into the extravascular space; gases are then not metabolized in the human body and are eliminated by the lungs, while the stabilising shells are eliminated by the liver[30].

CE-EUS can be performed by using color or power Doppler as a generic signal intensifier in Contrast-Enhanced Color and Power Doppler EUS (CE-EUS) or by using a dedicated contrast harmonic in Contrast-Enhanced Harmonic EUS (CH-EUS). Doppler has been historically useful for evaluating large blood vessels with fast-flowing blood but is not sensitive enough to detect slow and low-volume flow. Microbubble contrast agents increase the intensity of backscattered USs and can increase the Doppler signal of small vessels (arterioles and venules) with a diameter of approximately 0.1–0.4 mm, but not the signal of capillaries. Unfortunately, CE-EUS has several disadvantages such as blooming artefacts, vulnerability to motion artefacts and low sensitivity to slow flow[26,31].

Contrast harmonic techniques permit to improve the resolution of this method filtering signals originating from different tissues by selectively detecting harmonic components. Harmonic imaging is based on non-linear acoustic effects of US interactions with tissues or microbubble contrast agents. A linear system scatters signals with the same frequency as the transmitted pulse, differently a non-linear response contains both the original insonated frequency and harmonics, which are signals containing multiples of the transmitted frequency. When exposed to US waves, microbubbles resonate, releasing many harmonic signals; in this way a single bubble can be identified as a bright spot[32,33]. Through CH-EUS we can detect signals from microbubbles in vessels with very slow flow, as in the capillary bed, without Doppler-related artifacts[34].

During CH-EUS examination the echoendoscope is placed in front of the lesion of interest and, like in EUS-E, a reference B-mode image is kept beside the contrast enhanced image through a dual screen. In order to avoid breaking the microbubbles, a large intravenous catheter should be employed for the injection of the contrast agent, which should be administered slowly and followed by a saline flush. After the injection, the uptake and washout of the contrast agent are evaluated for at least 120 s: The microbubbles emit dynamically strong echo signals depicting large and small vessels and showing the microvasculature of the evaluated tissue, from the unenhanced phase to the contrast-enhanced phase. The internal vascular architecture influences the enhancement pattern, differentiated into 3 uptake patterns (hyper-enhancement, iso-enhancement, hypo-enhancement). For CH-EUS study low mechanical index (typically below 0.4, adjusted depending on the target) should be selected in order to obtain microbubble oscillation, to avoid their destruction and to obtain effective tissue signal suppression (non-linear response from tissue is minimal with low acoustic power)[26,31,35,36].

In recent years CH-EUS is achieving popularity, even if consensus is still lacking about its exact role in diagnostic workup of gastrointestinal lesions. It is commonly used in the investigation of pancreatic cystic and solid lesions, gallbladder abnormalities, subepithelial gastrointestinal tumors; other indications, such as staging of gastric tumors and other anomalies are limited to research studies. Indeed, the possibility of obtaining histological assessment through FNA or FNB with high diagnostic accuracy made this technique often unnecessary in daily clinical practice[14,32,37].

The European Federation of Societies for US in Medicine and Biology guidelines recommend the use of elastography and US contrast agents to increase the ability to distinguish benign or malignant nature of solid pancreatic tumors, pancreatic cystic neoplasms, and LNs. On the other hand, these methods could be used to improve the diagnostic performance of tissue sampling[38-41].

**EUS-GUIDED TISSUE ACQUISITION**

The introduction of EUS-FNA and FNB allowed a definite pathology for thoracic and abdominal masses. EUS combines the high-resolution US imaging of lesions and a safe and effective fine needle-based tissue acquisition of these lesions[11,42].

Several types of needles have been developed to provide histological tissue examination. Anyway, also standard aspiration needles (mainly larger needles) may provide the capture of tissue suitable for histopathological evaluation[43-47]. Histopathological handling is possible with small tissue cores fixed in formalin and, compared with cytopathological sample, it permits a wide variety of ancillary diagnostic techniques (immunohistochemistry, molecular analysis)[47,48]. Four main types of needle are currently available for EUS guided sampling: Standard aspiration needles (19-25 Gauge), biopsy needles with a core trap and reverse angle technology or with antegrade core trap (19-25 Gauge), needles with a shark-tip design (19-25 Gauge) and needles with a Franseen-type design (19-25 Gauge)[47,48].

The “fanning technique”, which permits to sample a large part of the target solid lesion or lymph node, represents the best EUS-sampling technique and is associated with a significant lower number of passes needed to establish the diagnosis[49]. “Suction technique” is used to facilitate EUS-guided tissue acquisition and consists in applying a negative suction pressure using a 5 mL or 10 mL syringe. On the other hand, the so-called “slow-pull technique”, consisting in the controlled pulling of the stylet allows a smooth negative pressure able to collect cytological specimens[50].

The amount of needle passes could be reduced based on on-site pathological evaluation (ROSE), where available, or should be based on gross visual inspection of the obtained material and the type of target lesion. A high number (≥ 7) of needle passes is thought to be a predictor of a high diagnostic sensitivity of EUS-FNA[51,52].

EUS-tissue acquisition is safe, with very low incidence of severe complications. No correlation among needle caliber and design and incidence of adverse events has been reported.

Perforation (0.03%–0.15%) is mainly due to the echoendoscope passage and not to the sampling procedure; limited data show that the perforation risk of EUS is similar to standard endoscopy.

The risk of acute pancreatitis following EUS-FNA is related to procedures which involve direct passage of the needle through the pancreas; the risk is higher in cystic than solid lesions sampling (0%-2%).

Severe bleeding following EUS-FNA is a rare event (0.13%), anyway an accurate evaluation between thromboembolic risk *vs* bleeding risk is mandatory before performing a EUS-guided intervention in patients on antiplatelet and/or anticoagulants therapy: Anticoagulant drug withdrawal should be considered based on patients’ risk assessment. A total platelet count lower than 50000/mmc and a prolonged prothrombin time (international normalized ratio greater than 1.5) should be considered a contraindication. No correlation among needle size, design, amount of passes has been related to an increased bleeding incidence[53,54].

Bacteremia and septic episodes following gastrointestinal EUS-FNA are rare events, comparable to that of standard diagnostic endoscopy; they are slightly more frequent in case of cystic lesions. In less than 1% of cases post-FNA fever was reported. Serious infectious complications have been reported following EUS-FNA of mediastinal cysts, ascites, perirectal cysts, pancreatic cystic lesions and pancreatic fluid collections. Guidelines recommend peri-interventional antibiotic treatment for EUS-FNA of pancreatic cystic lesions despite the absence of certain evidence, while the aspiration of mediastinal cysts is mainly contraindicated considering the potentially severe consequences of mediastinal infection[53-56].

EUS-guided sampling for malignant pancreatic tumors and for cholangiocarcinoma seems not to be a risk factor for the development of peritoneal seeding, tumor recurrence or decreased survival. The risk of peritoneal seeding following biopsy of pancreatic cancer appears to be significantly lower with EUS-FNA compared to percutaneous FNA[53,54].

**EUS LYMPH NODE EVALUATION**

***B-mode EUS***

Normal LNs have a characteristic B-mode appearance, with a typical two-layer architecture: An echo-poor cortex and a hyperechoic inner zone (hilum), which consists of fat and connective tissue, blood and lymph vessels. When using high-frequency probe, echo-poor or cystic follicles can sometimes be seen within the hypoechoic cortex. LNs shape is typically oval; supplying vessels can sometimes be seen entering the hilum with tree-like branches departing from the hilum to the cortex at color-Doppler evaluation[1,2]. The most important ultrasonographical features for differential diagnosis are size, shape, border, presence or absence of a central hilum, and cortical homogeneity (Figure 1)[57].

**Size:** The nodal size is the most relevant parameter for LNs nature diagnosis; all imaging modalities use size for the LNs differential diagnosis. Normal LN diameter varies according to their different locations (from 1 to 40 mm) and the best size parameter to evaluate is debated. As a general rule, LNs with diameter < 15 mm seem to grow mainly roundish by most pathological processes (both in inflammation and neoplastic infiltration); in LNs > 15-20 mm the main growth is on the longitudinal diameter, instead. Van den Brekel *et al*[58] proved that the minor axial diameter is the most accurate in predicting tumor positive nodes[58]. Anyway, both inflammation and malignant infiltration cause LNs enlargement and the distinction seems to be almost impossible when based only on nodal size: Even LNs with small diameters (< 3−5 mm) might be malignant, thus a higher limit value leads to higher specificity but lower sensitivity in differential diagnosis and it is not possible to set a reference value[4-6]. In gastrointestinal and pancreatic cancer about 50% of metastatic infiltrations are found in small LNs, sized ≤ 5 mm[7].

**Shape and border**: As a rule, normal LNs are oblong, except in some sites of head and neck. They present a sharp border, often not clearly distinguishable from the surrounding isoechoic fat. On the other hand, both inflammatory and malignant LNs show high delimitation based on an increased acoustic impedance gradient[2,59,60].

Most inflammatory LNs preserve their oval shape due to a homogeneous involvement by disease (LN heterogeneity is typical of granulomatous diseases such as tuberculosis). Neoplastic diseases affect mainly the cortex with multifocal arrangement and malignant LNs result typically large, roundish and asymmetric. Lymphomas affect the LN architecture diffusely, causing a roundish shape, while bulky masses appear only in the latest stage[61,62].

Longitudinal-to-short axis ratio, the so-called Solbiati-Index (SI), has been often proposed for differentiation of reactive and malignant LNs. A SI of less than 2 is supposed to be a criterion of malignancy, even if it is more sensitive in the head and neck region than in other sites, such as in axillary and inguinal region, where it’s often false-negative[63].

**Hilum:** Homogeneously hypoechoic LNs without hyperechoic hilum are often considered malignant because of neoplastic hilar infiltration. However, in the head and neck region also some normal and inflammatory LNs could show no hyperechoic hilum and, by contrast, an echogenic hilum can often be seen even in neoplastic LNs, mostly in early phases. In some cases, squamous cell carcinoma metastases can cause inner inhomogeneities which appear hyperechoic and can resemble the hilum[2,64].

**Echostructure:** LNs cortex is typical uniform, even if slight width fluctuation is considered normal. Its thickness is only evaluable in the presence of a visible hilum and its uniformity can often be analysed only in larger LNs. Cortical thickening occurs when cortex is > 50% of the main axis, and its thickness is considered asymmetric when it is at least double at one site than at the narrowest point. In inflammatory LNs with hypertrophic lymphatic follicles the cortex is typically concentrically widened, on the contrary eccentric cortical infiltration is an important sign of malignancy, even though cortex could be symmetrically involved in anaplastic carcinoma[2,63,65]. Lymphomas are diffuse diseases and often affect LNs cortex in a uniform way, even if it is not a rule.

Furthermore, the tendency toward necrotic and cystic degeneration of solid tumors can cause inhomogeneity of the internal structure of LNs, which is rare in lymphomas[2].

Faige *et al*[66] proposed a Visual analogue scale for the EUS assessment of LNs based on their B-mode appearance[66].

***Color-Doppler EUS***

In normal LNs arteries and veins enter through the hilum and branch towards the cortex, ending in subcapsular sinuous capillaries. In most inflammatory processes there is no significant change in vascular architecture and, in early stages, also metastatic LNs preserve original vascularity, sometimes increased by related immune reactions. In advanced stages bulky neoplastic infiltration and desmoplastic reaction distort and encase the original vascular structure and, due to the production of angiogenetic factors, tumors recruit capsular vessels leading to peripheral and intra-tumoral hypervascularity. Anyway, the vessel density of malignant LNs often depends on the type of primary tumor and neoplastic LNs often show avascular areas due to necrotic or cystic degeneration[38,67,68]. On color- and power-Doppler US, the vascular pattern of normal LNs is characterized by hilar vascularity without peripheral signals or by avascular pattern. The presence of peripheral flow is an important criterion for malignancy, even in small metastatic LNs and in lymphomas, which often show both hilar and peripheral vascularity. However, also tuberculous LNs can show abnormal vascularity, with eccentric hilar vessels and sometimes with peripheral pattern, leading to a difficult differential diagnosis from malignant ones. Increased vascularity in the surrounding inflammatory tissue can also mimic peripheral vascularity in case of inflammatory nodes[2,65,68].

In summary, most remarkable Doppler-EUS findings suggesting malignancy are: Displacement of vascular hilum, focal avascular areas, aberrant and subcapsular vessels[69]. Esen *et al*[65] described a sensitivity of 50% but specificity of 97% of color Doppler US criterion alone for the detection of metastatic LNs[65].

On spectral analysis, normal LNs hilar arteries present a resistive index (RI) < 0.75 and a pulsatility index (PI) usually lower than 1.6. Inflammatory LNs usually show a higher vascularity with RI < 0.8 and PI < 1.6. In metastatic LNs blood vessels within the capsule are compressed by tumor infiltration, and vascular resistance may rise, usually with high RI (> 0.8) and high PI (> 1.6)[2,67]. It was hypothesized that the intranodal pressure increases as long as the capsule is intact, with increased resistance and relative ischemia. A relative drop in RI can follow the decrease of pressure within the LN due to malignant infiltration of the capsule or to the presence of arteriovenous shunts in advanced architecture distortion[1,70,71]. The RI in lymphomatous LNs often measures intermediate values between reactive and metastatic LNs[2]. Table 1 summariza B-mode and color-Doppler criteria for LNs characterization.

***EUS-E***

FNA/FNB remains the gold standard technique for the determination of LNs malignant infiltration, with a positive predictive value (PPV) up to 100%, in this context elastography could be useful in selecting most suspicious LNs for tissue sampling, reducing unnecessary biopsies (Figure 2). EUS-E can detect even early neoplastic infiltration or small metastatic nodes. Elastography can also offer an alternative for the differential diagnosis in cases of negative biopsy or if tissue acquisition is not possible[7,18,72,73].

Giovannini *et al*[16] studied the ability of EUS-E in the differential diagnosis between benign and malignant LNs, highlighting its importance for guiding biopsy and showing higher sensitivity and specificity compared to B-mode EUS (91.8% and 82.5% *vs* 78.6% and 50.0%). PPV and NPV were of 88.8% and 86.8%, respectively[16]. Săftoiu *et al*[18] showed high 91.7% sens., 94.4% spec. and 92.9% diagnostic accuracy) in diagnostic differentiation using a qualitative analysis; even higher using quantitative histogram analysis, which is supposed to be less operator-dependent[18].

Malignant tissues are generally harder than normal tissues and elastography can give useful information for the distinction between benign and malignant LNs based on their stiffness. In most studies the elastography images have been scored according to different elastography patterns: LNs have been classified by EUS-E according to homogeneity and prevalent colour, distinguishing homogeneous (blue or green), heterogeneous or honeycombed pattern[17,73,74]. In particular, Giovannini *et al*[16] classified LNs as benign when qualitative EUS-E showed an homogeneous green pattern or an heterogeneous soft tissue (green, yellow and red tissue), malignant when homogeneously blue or mainly blue with one or some central areas of soft tissue (representing necrotic areas), suspicious when it showed an honeycomb pattern, with mixed hard and soft tissue.

In conclusion, EUS-E is an ancillary imaging method for LNs characterization and with an optimal diagnostic yield; in particular, EUS-E seems to increase the diagnostic yield in case of small LNs, which are difficult to characterize through B-mode and tissue acquisition. EUS-E provides diagnostic information to conventional B-mode imaging and can be used for the selection of suspicious LNs worth FNA/FNB thanks to its high PPV; EUS-E alone cannot obviate the need of tissue acquisition in suspected LNs[18,73,75].

***Contrast-enhanced EUS***

There are only few studies about the use of CE-EUS in the differential diagnosis of LNs.

CE-EUS permits to analyze nodal microvasculature (Figure 3): contrast enhancement pattern of inflammatory and normal LNs is characterized by centrifugal homogeneous enhancement due to hilum predominant vasculature; the difference between inflammatory and normal LNs is in the amount enhancement and not in the contrast pattern[32,76].

In metastatic LNs the normal capillary bed is destroyed by malignant infiltration, which also causes intranodal neoangiogenesis with development of pathological vessels. Thus, malignant LNs typically show a change in the perfusion pattern at CE-EUS with centripetal inhomogeneous enhancement due to abnormal neoplastic vessels, arteriovenous shunts and hypovascular areas, detected as focal hypoenhanced areas. For the same reasons malignant LNs also show longer contrast enhancement duration in comparison to benign ones. It’s possible to find avascular necrotic areas in granulomatous lymphadenopathies, such as tuberculosis and sarcoidosis leading to false positive results[32].

While color Doppler-EUS can study nodal vasculature only at the level of arterioles and venules, contrast harmonic mode can evaluate LNs microvasculature pattern. Thus, a massive lymph node involvement by malignancies could be detected even by CE-EUS, but tiny areas with abnormal capillary network within LNs can be revealed only at CH-EUS. In lymphomas CH-EUS nodal patterns are variable; the most common finding is intense homogeneous enhancement, not different from reactive LNs, because of preserved good vascularization in the capillary bed[32,37,77]. Finally, in case of CH-EUS non enhancement pattern, a colliquative necrosis could be deduced, suggesting the presence of inflammatory LN (*i.e.*, tubercular LN with extensive necrosis).

Like EUS-E, contrast-enhanced EUS could be used for FNA targeting, in order to choose the most suspicious LNs ant to select vital nodal areas: the identification of signs of neoangiogenesis and the detection of hypoenhancing necrotic areas may be useful in detecting malignant infiltration and in guiding biopsy[32].

A recent meta-analysis showed that CE-EUS has a poor pooled sensitivity (82.1%) and an optimal specificity (90.7%) in LNs differential diagnosis[14]; the use of dedicated CH-EUS slightly increases the diagnostic accuracy, with a pooled sensitivity of 87.7% and a pooled specificity of 91.8%. Anyway, recent guidelines still do not recommend CH-EUS for this indication[11,42].

The concomitance of more than one LN is a clear CH-EUS limit; in fact, LNs characterization is focused on the arterial and early venous phase. Repeated contrast administrations should be necessary. The use of B-mode and EUS-E to identify suspected LNs, and then CH-EUS to characterize in detail could be performed.

***EUS-guided tissue acquisition***

Making the correct differential diagnosis of mediastinal and abdominal lymphadenopathies is still challenging and tissue acquisition becomes often necessary: EUS provides an easy access to these LNs (Figure 1) and allows a better evaluation and possibly FNA/FNB even for small LNs[78].

European guidelines recommend EUS-tissue acquisition as first-line histological assessment of mediastinal or abdominal LNs if the pathological result modifies the patient’s management and if percutaneous biopsy is not possible[11,42].

EUS-guided tissue acquisition was proved to increase the diagnostic accuracy in diagnosis and staging and to have a good safety profile, probably related with the high spatial resolution of EUS, the proximity of target lesions to the EUS probe and the possibility to identify interposed vessels[79-82].

There is no robust evidence supporting the choice of different techniques for EUS LN sampling. Indeed, EUS-TA techniques are mainly assessed in solid pancreatic tumors, that are usually fibrotic and poorly cellulated. As described before, LNs architecture is different to pancreatic one: Malignant LNs are usually poorly fibrotic and highly cellulated. The results observed in solid pancreatic tumors are not 100% reproducible in this field. Therefore, needle choice, number of needle passes, type and amount of suction could only be deduced from knowledge in the field of solid pancreatic tumors needle aspiration.

False-negative results are mainly related to the characteristics of the lesion (size and nature of the tumor) and to technical aspects of EUS-FNA (sampling errors and interpretative errors). The presence of small lesions or of an interposed vascular structure between the transducer and the biopsy target can lead to inadequate or nonrepresentative samples. Furthermore, the presence of severe inflammation can hide an infiltrating tumor and cause histopathological errors[80,83].

Causes for false-positive results are epithelial cell contamination, EUS sampling error and pathological misinterpretation. Tumor cells can be present in luminal fluid and can enter the FNA needle as it passes through the gut lumen to reach the target lymph node. Main contaminants originate from the duodenal and gastric mucosa, but malignant cells are commonly present even in the luminal fluid of patients with pancreatic cancer and not only with luminal cancers. Furthermore, it is advised not to pass through the primary tumor with the needle when performing EUS-tissue acquisition of LNs, in order to avoid contamination. It is also plausible that false-positive results occur when the interposing mucosa is inflamed or in premalignant/early malignant state (such as in Barrett’s oesophagus with dysplasia or in chronic or autoimmune pancreatitis). In addition, even if uncommon, also the misinterpretation by cytopathologists can drive to wrong diagnosis[42,84,85].

Based on high-quality evidence, the rate of false-negative results is dramatically higher, compared to false-positive ones. This aspect could impact patients’ prognosis since the risk of under-staging with consequent under-treatment could not be excluded. In particular, in patients with early luminal gastrointestinal neoplasms *(i.e.* Barrett’s adenocarcinoma or early gastric cancer), the incorrect classification of a malignant LN could result in futile endoscopic resection and dramatic delay in curative surgery.

Cytopathologists and endoscopists should co-operate, sharing information about indications, clinical history and endoscopic technique, and increasing the level of their expertise, in order to reduce these kinds of errors and to increase the diagnostic value of this technique[82,85].

Okasha *et al*[78] reported a sensitivity and specificity of LNs EUS-FNA of 92% and 100%, respectively, with a very high PPV (100%) and a negative predictive value (NPV) of 88.1% in diagnosing malignant LNs[78].

A recent meta-analysis (26 studies, 2833 LNs) demonstrated that EUS-FNA present 87% pooled sensitivity with a 100% specificity, with an area under the curve of 0.99. The authors showed that sensitivity was slightly higher for abdominal (87%) than mediastinal (85%) LNs. Significant impact of ROSE was also observed (91% *vs* 85%)[86].

In 2020, another meta-analysis dealt with pooled diagnostic performance of EUS-FNA for abdominal LNs characterization[87]. The Authors included 12 studies (774 patients) and reported 94% pooled sensitivity and 98% specificity.

On the other hand, a meta-analysis conducted in 2008 was focused on the diagnostic accuracy of EUS-FNA on mediastinal LNs and showed a 88% pooled sensitivity and 96.4% pooled specificity[88]. Interestingly, this study clearly demonstrated that EUS-FNA diagnostic accuracy increased over time; indeed, studies conducted in 2000’s showed a pooled sensitivity of 91.7%[88].

To date, no randomized controlled study was designed to assess the difference between EUS-FNA and EUS-FNB for LNs characterization. A large trial comparing 20-gauge FNB needle to a standard 25-gauge FNA needle in 608 patients with solid lesions included a small proportion of LNs[89]. The Authors observed a trend toward a better accuracy in the FNB needle group (data on file; courtesy of Dr. Priscilla van Riet).

A large retrospective study enrolling 209 patients undergoing LN sampling. The Authors reported similar sensitivity (67% *vs* 75%) and diagnostic accuracy (79% *vs* 83%) for EUS-FNA and EUS-FNB, respectively, while a higher specificity was observed in EUS-FNB group (100% *vs* 94%). The Authors observed that ROSE availability increases the odd to obtain a correct diagnosis (Odd ratio 5.16 for accuracy)[90].

All studies reported a very low incidence of adverse events for EUS-guided LNs tissue acquisition. Pooled incidence was as low as 1.6% in published studies[86].

As demonstrated in the setting of solid pancreatic tumor, the diagnostic accuracy of EUS-guided tissue acquisition of LNs could be improved if used in combination to CH-EUS; the use of US contrast agent could be helpful not only in avoiding necrotic avascular areas, but also helping to identify the most suspicious LNs to be targeted[91].

High-quality evidence demonstrated that EUS-FNA is a sensitive, highly specific, and safe diagnostic tool for pathological characterization of mediastinal and abdominal LNs. Even if a positive impact is supposed, the role of EUS-FNB needles in this setting should be demonstrated yet.

**DIAGNOSTIC ALGORYTHM**

Table 2 summarize the diagnostic performance of EUS (B-mode and Dopppler), EUS-E, CH-EUS and EUS-guided tissue acquisition. While there is consensus on the low yield of B-mode EUS and Doppler criteria, the application of image enhancement techniques was not widely used, and final diagnosis was often based on EUS-guided tissue acquisition.

However, even in this setting, EUS-tissue acquisition is burdened by a not-negligible false negative rate, leading to a pooled sensitivity about 90%.

Outside clinical trials and tertiary centers, EUS-E presents high rates of undetermined cases due to technical failure (*i.e.* heartbeat artifacts) and CH-EUS is limited by difficult interpretation and sub-optimal sensitivity[92].

On these bases, our study group is conducting a prospective study, aimed to assess the combination of EUS-E and CH-EUS[92]. We found that the combination of the two techniques was significantly more accurate: the concordance of the two techniques shows a specificity and PPV of 100%. Interestingly, the sensitivity raised to 93.6% when at least one technique resulted negative (EUS-E “or” CH-EUS positive for malignancy). Finally, no patient with both techniques negative had a malignant LN (specificity for benign LNs 100%)[92].

The integration of the two techniques was able to overcome single limit; for example, CH-EUS was able to identify malignant necrotic LNs that appear “soft” on EUS-E but inhomogeneously enhanced on CH-EUS. On the other hand, EUS-E was able to identify lymphomas as “hard” LNs, that could appear benign, as homogeneously hyperenhanced, on CH-EUS.

**CONCLUSION**

In conclusion, as LNs characterization represent a crucial point for patients’ management, EUS must make use of all knowledge and ancillary techniques that could increase the diagnostic yield., avoiding the risk of false-negative tests, resulting in serious condition misdiagnosing or disease understaging, and the need of repeating EUS and tissue acquisition.

**REFERENCES**

1 **Weskott HP,** Ioanitescu ES. Diagnostic Approach to Lymph Node Diseases in Ultrasound. In: EFSUMB Course Book on Ultrasound. 1st ed. 2012: 189-224

2 **Cui XW**, Hocke M, Jenssen C, Ignee A, Klein S, Schreiber-Dietrich D, Dietrich CF. Conventional ultrasound for lymph node evaluation, update 2013. *Z Gastroenterol* 2014; **52**: 212-221 [PMID: 24526406 DOI: 10.1055/s-0033-1356153]

3 **Cho JW**. The Role of Endosonography in the Staging of Gastrointestinal Cancers. *Clin Endosc* 2015; **48**: 297-301 [PMID: 26240802 DOI: 10.5946/ce.2015.48.4.297]

4 **Mönig SP**, Zirbes TK, Schröder W, Baldus SE, Lindemann DG, Dienes HP, Hölscher AH. Staging of gastric cancer: correlation of lymph node size and metastatic infiltration. *AJR Am J Roentgenol* 1999; **173**: 365-367 [PMID: 10430138 DOI: 10.2214/ajr.173.2.10430138]

5 **Mönig SP**, Baldus SE, Zirbes TK, Schröder W, Lindemann DG, Dienes HP, Hölscher AH. Lymph node size and metastatic infiltration in colon cancer. *Ann Surg Oncol* 1999; **6**: 579-581 [PMID: 10493627 DOI: 10.1007/s10434-999-0579-1]

6 **Schröder W**, Baldus SE, Mönig SP, Beckurts TK, Dienes HP, Hölscher AH. Lymph node staging of esophageal squamous cell carcinoma in patients with and without neoadjuvant radiochemotherapy: histomorphologic analysis. *World J Surg* 2002; **26**: 584-587 [PMID: 12098049 DOI: 10.1007/s00268-001-0271-5]

7 **Dietrich CF**, Jenssen C, Arcidiacono PG, Cui XW, Giovannini M, Hocke M, Iglesias-Garcia J, Saftoiu A, Sun S, Chiorean L. Endoscopic ultrasound: Elastographic lymph node evaluation. *Endosc Ultrasound* 2015; **4**: 176-190 [PMID: 26374575 DOI: 10.4103/2303-9027.162995]

8 **Fujita A**, Ryozawa S, Mizuide M, Tanisaka Y, Ogawa T, Suzuki M, Katsuda H, Saito Y, Tashima T, Miyaguchi K, Arai E, Kawasaki T, Mashimo Y. Diagnosis of Pancreatic Solid Lesions, Subepithelial Lesions, and Lymph Nodes Using Endoscopic Ultrasound. *J Clin Med* 2021; **10** [PMID: 33807558 DOI: 10.3390/jcm10051076]

9 **Keter D,** Melzer E. Endoscopic ultrasound in clinical practice. *Acta Gastroenterol Latinoam* 2008; **38:** 146-151 [PMID: 18697409]

10 **Teshima CW,** Sandha GS. Endoscopic ultrasound in the diagnosis and treatment of pancreatic disease. *World J Gastroenterol* 2014; **20:** 9976-9989 [PMID: 25110426 DOI: 10.3748/wjg.v20.i29.9976]

11 **Dumonceau JM**, Deprez PH, Jenssen C, Iglesias-Garcia J, Larghi A, Vanbiervliet G, Aithal GP, Arcidiacono PG, Bastos P, Carrara S, Czakó L, Fernández-Esparrach G, Fockens P, Ginès À, Havre RF, Hassan C, Vilmann P, van Hooft JE, Polkowski M. Indications, results, and clinical impact of endoscopic ultrasound (EUS)-guided sampling in gastroenterology: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline - Updated January 2017. *Endoscopy* 2017; **49**: 695-714 [PMID: 28511234 DOI: 10.1055/s-0043-109021]

12 **Schizas D**, Ntanasis-Stathopoulos I, Tsilimigras DI, Sioulas AD, Moris D, Spartalis E, Scotiniotis I, Papanikolaou IS. The Role of Endoscopic Ultrasound in the Diagnosis and Management of Primary Gastric Lymphoma. *Gastroenterol Res Pract* 2017; **2017**: 2397430 [PMID: 28400819 DOI: 10.1155/2017/2397430]

13 **Labarca G**, Aravena C, Ortega F, Arenas A, Majid A, Folch E, Mehta HJ, Jantz MA, Fernandez-Bussy S. Minimally Invasive Methods for Staging in Lung Cancer: Systematic Review and Meta-Analysis. *Pulm Med* 2016; **2016**: 1024709 [PMID: 27818796 DOI: 10.1155/2016/1024709]

14 **Lisotti A**, Ricci C, Serrani M, Calvanese C, Sferrazza S, Brighi N, Casadei R, Fusaroli P. Contrast-enhanced endoscopic ultrasound for the differential diagnosis between benign and malignant lymph nodes: a meta-analysis. *Endosc Int Open* 2019; **7**: E504-E513 [PMID: 31044153 DOI: 10.1055/a-0854-3785]

15 **Takasaki Y**, Irisawa A, Shibukawa G, Sato A, Abe Y, Yamabe A, Arakawa N, Maki T, Yoshida Y, Igarashi R, Yamamoto S, Ikeda T. New endoscopic ultrasonography criteria for malignant lymphadenopathy based on inter-rater agreement. *PLoS One* 2019; **14**: e0212427 [PMID: 30794598 DOI: 10.1371/journal.pone.0212427]

16 **Giovannini M**, Thomas B, Erwan B, Christian P, Fabrice C, Benjamin E, Geneviève M, Paolo A, Pierre D, Robert Y, Walter S, Hanz S, Carl S, Christoph D, Pierre E, Jean-Luc VL, Jacques D, Peter V, Andrian S. Endoscopic ultrasound elastography for evaluation of lymph nodes and pancreatic masses: a multicenter study. *World J Gastroenterol* 2009; **15**: 1587-1593 [PMID: 19340900 DOI: 10.3748/wjg.15.1587]

17 **Giovannini M**, Hookey LC, Bories E, Pesenti C, Monges G, Delpero JR. Endoscopic ultrasound elastography: the first step towards virtual biopsy? Preliminary results in 49 patients. *Endoscopy* 2006; **38**: 344-348 [PMID: 16680632 DOI: 10.1055/s-2006-925158]

18 **Săftoiu A**, Vilmann P, Hassan H, Gorunescu F. Analysis of endoscopic ultrasound elastography used for characterisation and differentiation of benign and malignant lymph nodes. *Ultraschall Med* 2006; **27**: 535-542 [PMID: 17160759 DOI: 10.1055/s-2006-927117]

19 **Gettle LM**, Revzin MV. Innovations in Vascular Ultrasound. *Radiol Clin North Am* 2020; **58**: 653-669 [PMID: 32471536 DOI: 10.1016/j.rcl.2020.03.002]

20 **Sung JJ**. The use of color Doppler EUS in gastrointestinal diseases. *Endoscopy* 1998; **30 Suppl 1**: A149-A151 [PMID: 9765110 DOI: 10.1055/s-2007-1001500]

21 **Dietrich CF**, Bibby E, Jenssen C, Saftoiu A, Iglesias-Garcia J, Havre RF. EUS elastography: How to do it? *Endosc Ultrasound* 2018; **7**: 20-28 [PMID: 29451165 DOI: 10.4103/eus.eus\_49\_17]

22 **Iglesias-García J**, Lariño-Noia J, Domínguez-Muñoz JE. New Imaging Techniques: Endoscopic Ultrasound-Guided Elastography. *Gastrointest Endosc Clin N Am* 2017; **27**: 551-567 [PMID: 28918798 DOI: 10.1016/j.giec.2017.06.001]

23 **Iglesias-Garcia J**, Lindkvist B, Lariño-Noia J, Domínguez-Muñoz JE. Endoscopic ultrasound elastography. *Endosc Ultrasound* 2012; **1**: 8-16 [PMID: 24949330 DOI: 10.7178/eus.01.003]

24 **Dietrich CF**, Cantisani V. Current status and perspectives of elastography. *Eur J Radiol* 2014; **83**: 403-404 [PMID: 23540945 DOI: 10.1016/j.ejrad.2013.02.028]

25 **Havre RF**, Elde E, Gilja OH, Odegaard S, Eide GE, Matre K, Nesje LB. Freehand real-time elastography: impact of scanning parameters on image quality and in vitro intra- and interobserver validations. *Ultrasound Med Biol* 2008; **34**: 1638-1650 [PMID: 18524458 DOI: 10.1016/j.ultrasmedbio.2008.03.009]

26 **Knauth Meadows A,** Ordovas K, Higgins CB, Reddy GP. Magnetic resonance imaging in the adult with congenital heart disease. *Semin Roentgenol* 2008; **43:** 246-258 [PMID: 18486685 DOI: 10.1053/j.ro.2008.02.009]

27 **Iglesias-Garcia J**, Lindkvist B, Lariño-Noia J, Abdulkader-Nallib I, Dominguez-Muñoz JE. Differential diagnosis of solid pancreatic masses: contrast-enhanced harmonic (CEH-EUS), quantitative-elastography (QE-EUS), or both? *United European Gastroenterol J* 2017; **5**: 236-246 [PMID: 28344791 DOI: 10.1177/2050640616640635]

28 **Kitano M**, Yamashita Y. New Imaging Techniques for Endoscopic Ultrasonography: Contrast-Enhanced Endoscopic Ultrasonography. *Gastrointest Endosc Clin N Am* 2017; **27**: 569-583 [PMID: 28918799 DOI: 10.1016/j.giec.2017.06.002]

29 **Dietrich CF**, Sharma M, Hocke M. Contrast-enhanced endoscopic ultrasound. *Endosc Ultrasound* 2012; **1**: 130-136 [PMID: 24949350 DOI: 10.7178/eus.03.003]

30 **Baert A,** Sartor K. Contrast media in ultrasonography. In: Quaia E, editor Basic principles and clinical applications. 1st ed. Berlin: Springer, 2005: 3-14

31 **Alvarez-Sánchez MV**, Napoléon B. Contrast-enhanced harmonic endoscopic ultrasound imaging: basic principles, present situation and future perspectives. *World J Gastroenterol* 2014; **20**: 15549-15563 [PMID: 25400439 DOI: 10.3748/wjg.v20.i42.15549]

32 **Hocke M**, Ignee A, Dietrich C. Role of contrast-enhanced endoscopic ultrasound in lymph nodes. *Endosc Ultrasound* 2017; **6**: 4-11 [PMID: 28218194 DOI: 10.4103/2303-9027.190929]

33 **Lencioni R**, Cioni D, Bartolozzi C. Tissue harmonic and contrast-specific imaging: back to gray scale in ultrasound. *Eur Radiol* 2002; **12**: 151-165 [PMID: 11868093 DOI: 10.1007/s003300101022]

34 **Kitano M**, Sakamoto H, Matsui U, Ito Y, Maekawa K, von Schrenck T, Kudo M. A novel perfusion imaging technique of the pancreas: contrast-enhanced harmonic EUS (with video). *Gastrointest Endosc* 2008; **67**: 141-150 [PMID: 18155437 DOI: 10.1016/j.gie.2007.07.045]

35 **Dietrich CF**, Ignee A, Frey H. Contrast-enhanced endoscopic ultrasound with low mechanical index: a new technique. *Z Gastroenterol* 2005; **43**: 1219-1223 [PMID: 16267707 DOI: 10.1055/s-2005-858662]

36 **Fusaroli P,** Kypraios D, Caletti G, Eloubeidi MA. Pancreatico-biliary endoscopic ultrasound: a systematic review of the levels of evidence, performance and outcomes. *World J Gastroenterol* 2012; **18:** 4243-4256 [PMID: 22969187 DOI: 10.3748/wjg.v18.i32.4243]

37 **Cui XW**, Jenssen C, Saftoiu A, Ignee A, Dietrich CF. New ultrasound techniques for lymph node evaluation. *World J Gastroenterol* 2013; **19**: 4850-4860 [PMID: 23946589 DOI: 10.3748/wjg.v19.i30.4850]

38 **Piscaglia F**, Nolsøe C, Dietrich CF, Cosgrove DO, Gilja OH, Bachmann Nielsen M, Albrecht T, Barozzi L, Bertolotto M, Catalano O, Claudon M, Clevert DA, Correas JM, D'Onofrio M, Drudi FM, Eyding J, Giovannini M, Hocke M, Ignee A, Jung EM, Klauser AS, Lassau N, Leen E, Mathis G, Saftoiu A, Seidel G, Sidhu PS, ter Haar G, Timmerman D, Weskott HP. The EFSUMB Guidelines and Recommendations on the Clinical Practice of Contrast Enhanced Ultrasound (CEUS): update 2011 on non-hepatic applications. *Ultraschall Med* 2012; **33**: 33-59 [PMID: 21874631 DOI: 10.1055/s-0031-1281676]

39 **Cosgrove D**, Piscaglia F, Bamber J, Bojunga J, Correas JM, Gilja OH, Klauser AS, Sporea I, Calliada F, Cantisani V, D'Onofrio M, Drakonaki EE, Fink M, Friedrich-Rust M, Fromageau J, Havre RF, Jenssen C, Ohlinger R, Săftoiu A, Schaefer F, Dietrich CF; EFSUMB. EFSUMB guidelines and recommendations on the clinical use of ultrasound elastography. Part 2: Clinical applications. *Ultraschall Med* 2013; **34**: 238-253 [PMID: 23605169 DOI: 10.1055/s-0033-1335375]

40 **Kamata K**, Takenaka M, Kitano M, Omoto S, Miyata T, Minaga K, Yamao K, Imai H, Sakurai T, Watanabe T, Nishida N, Chikugo T, Chiba Y, Imamoto H, Yasuda T, Lisotti A, Fusaroli P, Kudo M. Contrast-enhanced harmonic endoscopic ultrasonography for differential diagnosis of submucosal tumors of the upper gastrointestinal tract. *J Gastroenterol Hepatol* 2017; **32**: 1686-1692 [PMID: 28220958 DOI: 10.1111/jgh.13766]

41 **Fusaroli P,** Eloubeidi MA. Diagnosis of pancreatic cancer by contrast-harmonic endoscopic ultrasound (EUS): complementary and not competitive with EUS-guided fine-needle aspiration. *Endoscopy* 2014; **46**: 380-381 [DOI: 10.1055/s-0034-1365425]

42 **Fusaroli P**, Jenssen C, Hocke M, Burmester E, Buscarini E, Havre RF, Ignee A, Saftoiu A, Vilmann P, Nolsøe CP, Nürnberg D, D'Onofrio M, Gilja OH, Lorentzen T, Piscaglia F, Sidhu PS, Dietrich CF. EFSUMB Guidelines on Interventional Ultrasound (INVUS), Part V - EUS-Guided Therapeutic Interventions (short version). *Ultraschall Med* 2016; **37**: 412-420 [PMID: 27490463 DOI: 10.1055/s-0035-1553742]

43 **Panic N**, Larghi A. Techniques for endoscopic ultrasound-guided fine-needle biopsy. *Gastrointest Endosc Clin N Am* 2014; **24**: 83-107 [PMID: 24215762 DOI: 10.1016/j.giec.2013.08.010]

44 **Dietrich CF**, Jenssen C. Endoscopic ultrasound-guided sampling in gastroenterology: European society of gastrointestinal endoscopy technical guidelines. *Endosc Ultrasound* 2013; **2**: 117-122 [PMID: 24949378 DOI: 10.7178/eus.06.001]

45 **Varadarajulu S**, Fraig M, Schmulewitz N, Roberts S, Wildi S, Hawes RH, Hoffman BJ, Wallace MB. Comparison of EUS-guided 19-gauge Trucut needle biopsy with EUS-guided fine-needle aspiration. *Endoscopy* 2004; **36**: 397-401 [PMID: 15100946 DOI: 10.1055/s-2004-814316]

46 **Varadarajulu S**, Hawes RH. The changing paradigm in EUS-guided tissue acquisition. *Gastrointest Endosc Clin N Am* 2014; **24**: 1-7 [PMID: 24215756 DOI: 10.1016/j.giec.2013.08.006]

47 **Polkowski M**, Jenssen C, Kaye P, Carrara S, Deprez P, Gines A, Fernández-Esparrach G, Eisendrath P, Aithal GP, Arcidiacono P, Barthet M, Bastos P, Fornelli A, Napoleon B, Iglesias-Garcia J, Seicean A, Larghi A, Hassan C, van Hooft JE, Dumonceau JM. Technical aspects of endoscopic ultrasound (EUS)-guided sampling in gastroenterology: European Society of Gastrointestinal Endoscopy (ESGE) Technical Guideline - March 2017. *Endoscopy* 2017; **49**: 989-1006 [PMID: 28898917 DOI: 10.1055/s-0043-119219]

48 **Hébert-Magee S**. How can an endosonographer assess for diagnostic sufficiency and options for handling the endoscopic ultrasound-guided fine-needle aspiration specimen and ancillary studies. *Gastrointest Endosc Clin N Am* 2014; **24**: 29-56 [PMID: 24215759 DOI: 10.1016/j.giec.2013.08.002]

49 **Bang JY**, Magee SH, Ramesh J, Trevino JM, Varadarajulu S. Randomized trial comparing fanning with standard technique for endoscopic ultrasound-guided fine-needle aspiration of solid pancreatic mass lesions. *Endoscopy* 2013; **45**: 445-450 [PMID: 23504490 DOI: 10.1055/s-0032-1326268]

50 **Tarantino I**, Di Mitri R, Fabbri C, Pagano N, Barresi L, Granata A, Liotta R, Mocciaro F, Maimone A, Baccarini P, Fabio T, Curcio G, Repici A, Traina M. Is diagnostic accuracy of fine needle aspiration on solid pancreatic lesions aspiration-related? A multicentre randomised trial. *Dig Liver Dis* 2014; **46**: 523-526 [PMID: 24704290 DOI: 10.1016/j.dld.2014.02.023]

51 **Dumonceau JM**, Koessler T, van Hooft JE, Fockens P. Endoscopic ultrasonography-guided fine needle aspiration: Relatively low sensitivity in the endosonographer population. *World J Gastroenterol* 2012; **18**: 2357-2363 [PMID: 22654426 DOI: 10.3748/wjg.v18.i19.2357]

52 **Lisotti A**, Frazzoni L, Fuccio L, Serrani M, Cominardi A, Bazzoli F, Fusaroli P. Repeat EUS-FNA of pancreatic masses after nondiagnostic or inconclusive results: systematic review and meta-analysis. *Gastrointest Endosc* 2020; **91**: 1234-1241.e4 [PMID: 32006546 DOI: 10.1016/j.gie.2020.01.034]

53 **ASGE Standards of Practice Committee.**, Early DS, Acosta RD, Chandrasekhara V, Chathadi KV, Decker GA, Evans JA, Fanelli RD, Fisher DA, Fonkalsrud L, Hwang JH, Jue TL, Khashab MA, Lightdale JR, Muthusamy VR, Pasha SF, Saltzman JR, Sharaf RN, Shergill AK, Cash BD. Adverse events associated with EUS and EUS with FNA. *Gastrointest Endosc* 2013; **77**: 839-843 [PMID: 23684089 DOI: 10.1016/j.gie.2013.02.018]

54 **Polkowski M**, Larghi A, Weynand B, Boustière C, Giovannini M, Pujol B, Dumonceau JM; European Society of Gastrointestinal Endoscopy (ESGE). Learning, techniques, and complications of endoscopic ultrasound (EUS)-guided sampling in gastroenterology: European Society of Gastrointestinal Endoscopy (ESGE) Technical Guideline. *Endoscopy* 2012; **44**: 190-206 [PMID: 22180307 DOI: 10.1055/s-0031-1291543]

55 **Voss M**, Hammel P, Molas G, Palazzo L, Dancour A, O'Toole D, Terris B, Degott C, Bernades P, Ruszniewski P. Value of endoscopic ultrasound guided fine needle aspiration biopsy in the diagnosis of solid pancreatic masses. *Gut* 2000; **46**: 244-249 [PMID: 10644320 DOI: 10.1136/gut.46.2.244]

56 **Guarner-Argente C**, Shah P, Buchner A, Ahmad NA, Kochman ML, Ginsberg GG. Use of antimicrobials for EUS-guided FNA of pancreatic cysts: a retrospective, comparative analysis. *Gastrointest Endosc* 2011; **74**: 81-86 [PMID: 21704808 DOI: 10.1016/j.gie.2011.03.1244]

57 **Tregnaghi A**, De Candia A, Calderone M, Cellini L, Rossi CR, Talenti E, Blandamura S, Borsato S, Muzzio PC, Rubaltelli L. Ultrasonographic evaluation of superficial lymph node metastases in melanoma. *Eur J Radiol* 1997; **24**: 216-221 [PMID: 9232392 DOI: 10.1016/s0720-048x(96)01102-3]

58 **van den Brekel MW**, Stel HV, Castelijns JA, Nauta JJ, van der Waal I, Valk J, Meyer CJ, Snow GB. Cervical lymph node metastasis: assessment of radiologic criteria. *Radiology* 1990; **177**: 379-384 [PMID: 2217772 DOI: 10.1148/radiology.177.2.2217772]

59 **Shozushima M**, Suzuki M, Nakasima T, Yanagisawa Y, Sakamaki K, Takeda Y. Ultrasound diagnosis of lymph node metastasis in head and neck cancer. *Dentomaxillofac Radiol* 1990; **19**: 165-170 [PMID: 2097226 DOI: 10.1259/dmfr.19.4.2097226]

60 **Ahuja A**, Ying M, King A, Yuen HY. Lymph node hilus: gray scale and power Doppler sonography of cervical nodes. *J Ultrasound Med* 2001; **20**: 987-92; quiz 994 [PMID: 11549160 DOI: 10.7863/jum.2001.20.9.987]

61 **Ahuja AT**, Ying M. Sonographic evaluation of cervical lymph nodes. *AJR Am J Roentgenol* 2005; **184**: 1691-1699 [PMID: 15855141 DOI: 10.2214/ajr.184.5.01841691]

62 **Barreiros AP**, Braden B, Schieferstein-Knauer C, Ignee A, Dietrich CF. Characteristics of intestinal tuberculosis in ultrasonographic techniques. *Scand J Gastroenterol* 2008; **43**: 1224-1231 [PMID: 18609146 DOI: 10.1080/00365520802158606]

63 **Vassallo P**, Wernecke K, Roos N, Peters PE. Differentiation of benign from malignant superficial lymphadenopathy: the role of high-resolution US. *Radiology* 1992; **183**: 215-220 [PMID: 1549675 DOI: 10.1148/radiology.183.1.1549675]

64 **Gritzmann N**, Hollerweger A, Macheiner P, Rettenbacher T. Sonography of soft tissue masses of the neck. *J Clin Ultrasound* 2002; **30**: 356-373 [PMID: 12116098 DOI: 10.1002/jcu.10073]

65 **Esen G**, Gurses B, Yilmaz MH, Ilvan S, Ulus S, Celik V, Farahmand M, Calay OO. Gray scale and power Doppler US in the preoperative evaluation of axillary metastases in breast cancer patients with no palpable lymph nodes. *Eur Radiol* 2005; **15**: 1215-1223 [PMID: 15690206 DOI: 10.1007/s00330-004-2605-9]

66 **Faige DO**. EUS in patients with benign and malignant lymphadenopathy. *Gastrointest Endosc* 2001; **53**: 593-598 [PMID: 11323584 DOI: 10.1067/mge.2001.114060]

67 **Steinkamp HJ**, Wissgott C, Rademaker J, Felix R. Current status of power Doppler and color Doppler sonography in the differential diagnosis of lymph node lesions. *Eur Radiol* 2002; **12**: 1785-1793 [PMID: 12111070 DOI: 10.1007/s003300101111]

68 **Kamata K**, Takenaka M, Kitano M, Omoto S, Miyata T, Minaga K, Yamao K, Imai H, Sakurai T, Nishida N, Kashida H, Chikugo T, Chiba Y, Nakai T, Takeyama Y, Lisotti A, Fusaroli P, Kudo M. Contrast-enhanced harmonic endoscopic ultrasonography for differential diagnosis of localized gallbladder lesions. *Dig Endosc* 2018; **30**: 98-106 [PMID: 28632914 DOI: 10.1111/den.12900]

69 **Tschammler A**, Ott G, Schang T, Seelbach-Goebel B, Schwager K, Hahn D. Lymphadenopathy: differentiation of benign from malignant disease--color Doppler US assessment of intranodal angioarchitecture. *Radiology* 1998; **208**: 117-123 [PMID: 9646801 DOI: 10.1148/radiology.208.1.9646801]

70 **Chang DB**, Yuan A, Yu CJ, Luh KT, Kuo SH, Yang PC. Differentiation of benign and malignant cervical lymph nodes with color Doppler sonography. *AJR Am J Roentgenol* 1994; **162**: 965-968 [PMID: 8141027 DOI: 10.2214/ajr.162.4.8141027]

71 **Yamashita Y**, Shimokawa T, Napoléon B, Fusaroli P, Gincul R, Kudo M, Kitano M. Value of contrast-enhanced harmonic endoscopic ultrasonography with enhancement pattern for diagnosis of pancreatic cancer: A meta-analysis. *Dig Endosc* 2019; **31**: 125-133 [PMID: 30338569 DOI: 10.1111/den.13290]

72 **Fusaroli P**, D'Ercole MC, De Giorgio R, Serrani M, Caletti G. Contrast harmonic endoscopic ultrasonography in the characterization of pancreatic metastases (with video). *Pancreas* 2014; **43**: 584-587 [PMID: 24713844 DOI: 10.1097/MPA.0000000000000081]

73 **Janssen J**, Dietrich CF, Will U, Greiner L. Endosonographic elastography in the diagnosis of mediastinal lymph nodes. *Endoscopy* 2007; **39**: 952-957 [PMID: 18008203 DOI: 10.1055/s-2007-966946]

74 **Altonbary AY**, Hakim H, El-Shamy AM. Endoscopic Ultrasound Elastography for Evaluation of Lymph Nodes: A Single Center Experience. *Diagn Ther Endosc* 2018; **2018**: 7186341 [PMID: 30425445 DOI: 10.1155/2018/7186341]

75 **Xu W**, Shi J, Zeng X, Li X, Xie WF, Guo J, Lin Y. EUS elastography for the differentiation of benign and malignant lymph nodes: a meta-analysis. *Gastrointest Endosc* 2011; **74**: 1001-9; quiz 1115.e1-4 [PMID: 22032315 DOI: 10.1016/j.gie.2011.07.026]

76 **Hocke M**, Menges M, Topalidis T, Dietrich CF, Stallmach A. Contrast-enhanced endoscopic ultrasound in discrimination between benign and malignant mediastinal and abdominal lymph nodes. *J Cancer Res Clin Oncol* 2008; **134**: 473-480 [PMID: 17891499 DOI: 10.1007/s00432-007-0309-7]

77 **Jin Y**, He YS, Zhang MM, Parajuly SS, Chen S, Zhao HN, Peng YL. Value of contrast-enhanced ultrasonography in the differential diagnosis of enlarged lymph nodes: a meta-analysis of diagnostic accuracy studies. *Asian Pac J Cancer Prev* 2015; **16**: 2361-2368 [PMID: 25824765 DOI: 10.7314/apjcp.2015.16.6.2361]

78 **Okasha H**, Elkholy S, Sayed M, Salman A, Elsherif Y, El-Gemeie E. Endoscopic ultrasound-guided fine-needle aspiration and cytology for differentiating benign from malignant lymph nodes. *Arab J Gastroenterol* 2017; **18**: 74-79 [PMID: 28624157 DOI: 10.1016/j.ajg.2017.05.015]

79 **Stelow EB**, Lai R, Bardales RH, Mallery S, Linzie BM, Crary G, Stanley MW. Endoscopic ultrasound-guided fine-needle aspiration of lymph nodes: the Hennepin County Medical Center experience. *Diagn Cytopathol* 2004; **30**: 301-306 [PMID: 15108226 DOI: 10.1002/dc.10405]

80 **Bardales RH**, Stelow EB, Mallery S, Lai R, Stanley MW. Review of endoscopic ultrasound-guided fine-needle aspiration cytology. *Diagn Cytopathol* 2006; **34**: 140-175 [PMID: 16511852 DOI: 10.1002/dc.20300]

81 **Williams DB**, Sahai AV, Aabakken L, Penman ID, van Velse A, Webb J, Wilson M, Hoffman BJ, Hawes RH. Endoscopic ultrasound guided fine needle aspiration biopsy: a large single centre experience. *Gut* 1999; **44**: 720-726 [PMID: 10205212 DOI: 10.1136/gut.44.5.720]

82 **Chin YK**, Iglesias-Garcia J, de la Iglesia D, Lariño-Noia J, Abdulkader-Nallib I, Lázare H, Rebolledo Olmedo S, Dominguez-Muñoz JE. Accuracy of endoscopic ultrasound-guided tissue acquisition in the evaluation of lymph nodes enlargement in the absence of on-site pathologist. *World J Gastroenterol* 2017; **23**: 5755-5763 [PMID: 28883701 DOI: 10.3748/wjg.v23.i31.5755]

83 **Eloubeidi MA**, Jhala D, Chhieng DC, Chen VK, Eltoum I, Vickers S, Mel Wilcox C, Jhala N. Yield of endoscopic ultrasound-guided fine-needle aspiration biopsy in patients with suspected pancreatic carcinoma. *Cancer* 2003; **99**: 285-292 [PMID: 14579295 DOI: 10.1002/cncr.11643]

84 **van Hemel BM**, Lamprou AA, Weersma R, Plukker JT, Suurmeijer AJ, van Dullemen HM. Procedure-related, false-positive cytology results during EUS-guided FNA in patients with esophageal cancer. *Gastrointest Endosc* 2010; **71**: 1130-1133 [PMID: 20598243 DOI: 10.1016/j.gie.2010.01.051]

85 **Gleeson FC**, Kipp BR, Caudill JL, Clain JE, Clayton AC, Halling KC, Henry MR, Rajan E, Topazian MD, Wang KK, Wiersema MJ, Zhang J, Levy MJ. False positive endoscopic ultrasound fine needle aspiration cytology: incidence and risk factors. *Gut* 2010; **59**: 586-593 [PMID: 20427392 DOI: 10.1136/gut.2009.187765]

86 **Chen L,** Li Y, Gao X, Lin S, He L, Luo G, Li J, Huang C, Wang G, Yang Q, Shan H. High Diagnostic Accuracy and Safety of Endoscopic Ultrasound-Guided Fine-Needle Aspiration in Malignant Lymph Nodes: A Systematic Review and Meta-Analysis. *Dig Dis Sci* 2020 [PMID: 32979158 DOI: 10.1007/s10620-020-06554-2]

87 **Li C**, Shuai Y, Zhou X. Endoscopic ultrasound guided fine needle aspiration for the diagnosis of intra-abdominal lymphadenopathy: a systematic review and meta-analysis. *Scand J Gastroenterol* 2020; **55**: 114-122 [PMID: 31881165 DOI: 10.1080/00365521.2019.1704052]

88 **Puli SR**, Batapati Krishna Reddy J, Bechtold ML, Ibdah JA, Antillon D, Singh S, Olyaee M, Antillon MR. Endoscopic ultrasound: it's accuracy in evaluating mediastinal lymphadenopathy? A meta-analysis and systematic review. *World J Gastroenterol* 2008; **14**: 3028-3037 [PMID: 18494054 DOI: 10.3748/wjg.14.3028]

89 **van Riet PA**, Larghi A, Attili F, Rindi G, Nguyen NQ, Ruszkiewicz A, Kitano M, Chikugo T, Aslanian H, Farrell J, Robert M, Adeniran A, Van Der Merwe S, Roskams T, Chang K, Lin F, Lee JG, Arcidiacono PG, Petrone M, Doglioni C, Iglesias-Garcia J, Abdulkader I, Giovannini M, Bories E, Poizat F, Santo E, Scapa E, Marmor S, Bucobo JC, Buscaglia JM, Heimann A, Wu M, Baldaque-Silva F, Moro CF, Erler NS, Biermann K, Poley JW, Cahen DL, Bruno MJ. A multicenter randomized trial comparing a 25-gauge EUS fine-needle aspiration device with a 20-gauge EUS fine-needle biopsy device. *Gastrointest Endosc* 2019; **89**: 329-339 [PMID: 30367877 DOI: 10.1016/j.gie.2018.10.026]

90 **de Moura DTH**, McCarty TR, Jirapinyo P, Ribeiro IB, Farias GFA, Ryou M, Lee LS, Thompson CC. Endoscopic Ultrasound Fine-Needle Aspiration versus Fine-Needle Biopsy for Lymph Node Diagnosis: A Large Multicenter Comparative Analysis. *Clin Endosc* 2020; **53**: 600-610 [PMID: 31794654 DOI: 10.5946/ce.2019.170]

91 **Facciorusso A,** Mohan BP, Crinò SF, Ofosu A, Ramai D, Lisotti A, Chandan S, Fusaroli P. Contrast-enhanced harmonic endoscopic ultrasound-guided fine-needle aspiration vs standard fine-needle aspiration in pancreatic masses: a meta-analysis. *Expert Rev Gastroenterol Hepatol* 2021; 1-8 [DOI: 10.1055/s-0041-1724432]

92 **Lisotti A**, Fusaroli P. Contrast-enhanced EUS for the differential diagnosis of lymphadenopathy: technical improvement with defined indications. *Gastrointest Endosc* 2019; **90**: 995-996 [PMID: 31759423 DOI: 10.1016/j.gie.2019.06.037]

**Footnotes**

**Conflict-of-interest statement:** Authors declare no conflict of interests for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** February 21, 2021

**First decision:** April 6, 2021

**Article in press:**

**Specialty type:** Oncology

**Country/Territory of origin:** Italy

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): C

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Chen L, Wang G **S-Editor:** Fan JR **L-Editor: P-Editor:**

**Figure Legends**



**Figure 1 Endoscopic ultrasound B-mode criteria of a malignant lymph node (mediastinal metastasis from breast cancer), and endoscopic ultrasound-guided tissue acquisition.**



**Figure 2 Endoscopic ultrasound elastography of a malignant lymph node (abdominal metastasis from gastric cancer).**



**Figure 3 Contrast-enhanced harmonic endoscopic ultrasound appearance of a malignant lymph node (abdominal lymphoma).**

**Table 1** **Endoscopic ultrasound B-mode and color-Doppler criteria for the characterization of suspected lymph nodes**

|  |  |  |
| --- | --- | --- |
|  | **Benign LNs** | **Malignant LNs** |
| **B-mode criteria** |  |  |
| Shape | Oval | Round |
| Border | Irregular shape | Clear-cut, asymmetric |
| Echogenicity | Hyperechoic | Hypoechoic |
| Vascular hilum | Present, central | Absent |
| Echostructure | Heterogeneous | Homogeneous |
| **Color-Doppler criteria** |  |  |
| Hilar doppler sign | Present | Absent or displaced |
| Subcapsular vessels | Absent | Often present |
| Avascular areas | Absent | Often present |
| Resistance index | < 0.8 | > 0.8 |

LNs: Lymph nodes.

**Table 2** **Summary of diagnostic performance of B-mode endoscopic ultrasound, elastography, contrast-enhanced harmonic endoscopic ultrasound and endoscopic ultrasound-guided fine needle aspiration for lymph nodes characterization**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Pooled sensitivity** | **Pooled specificity** | **Area under the curve** | **Ref.** |
| EUS (B-mode + Doppler) | 84.7% | 84.6% | 0.91 | Puli *et al*[88], 2008 |
| EUS-E | 88% | 85% | 0.95 | Xu *et al*[75], 2011 |
| CH-EUS | 87.7% | 91.8% | 0.97 | Lisotti *et al*[14], 2019 |
| Combined EUS-E + CH-EUS1 | 43.6% | 100% | 0.92 | Lisotti *et al*[92], 2019 |
| Combined EUS-E “or” CH-EUS2 | 93.6% | 87.5% | 0.91 | Lisotti *et al*[92], 2019 |
| EUS-FNA | 87% | 100% | 0.99 | Chen *et al*[86], 2020 |

1Both endoscopic ultrasound-elastography (EUS-E) and contrast-enhanced harmonic EUS (CH-EUS) positive for malignancy; 2At least one technique (EUE-E or CH-EUS) positive for malignancy. EUS: Endoscopic ultrasound; EUS-E: EUS-elastography; CH-EUS: Contrast-enhanced harmonic EUS; EUS-FNA: EUS-guided fine needle aspiration.